Emerging Targeted Therapies in IgAN: A Systematic Review Without Meta-Analysis (SWiM) of Phase 3 Randomized Controlled Trials (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0642; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "All treatments reduced UPCR versus control groups: 27% for Nefecon at 9 months, 51.2% for sibeprenlimab at 9 months, 38.3% iptacopan at 9 months, 36.1% for atrasentan at 36 weeks, and 41% for sparsentan at 36 weeks (all 95% confidence intervals exclude zero)...Sparsentan was associated with reduction in chronic eGFR slope versus irbesartan (1.1 mL/min/1.73m2/yr), although total slope did not reach statistical significance...Conclusion The five phase 3 RCTs of targeted therapies in IgAN demonstrated reductions in proteinuria and, in several trials, slowing of eGFR decline, supporting potential disease-modifying effects. However, interpretation is limited by reliance on surrogate endpoints, and longer-term follow-up is needed to confirm effects on kidney failure and safety outcomes."
P3 data • Retrospective data • Review • Glomerulonephritis • IgA Nephropathy • Infectious Disease • Nephrology • Renal Disease
|
|
Mohamed Bouzed; Alla Bouzed; Khalid M.G Mohammed; Muner Mohamed
|